Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101 (SPARC-LI)

28 de octubre de 2026 actualizado por: Kerry Ressler, Mclean Hospital

SPARC-LI: Synaptic Plasticity Augmented Rapid Circuit Stimulation

In this pilot study, investigators aim to combine D-cycloserine, lurasidone, and single-day repeated intermittent Theta Burst Stimulation (iTBS) to preliminarily assess clinical improvement in an open-label cohort and monitor for adverse events over a 6-week follow-up period.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Current therapeutic approaches for depression are limited in efficacy and accessibility. For many patients, Transcranial Magnetic Stimulation (TMS) has provided relief from treatment-resistant depression; however, invetigators are still far from maximizing the benefits of TMS. Here, investigators combine state-of-the-art interventions proven in depression (D-cycloserine (DCS), lurasidone (LRD), rapid intermittent Theta Burst Stimulation (iTBS)) with the aim of inducing and capitalizing on brain plasticity to support the alleviation of depressive symptoms.

The rationale for pharmacologically augmenting TMS is that 100 mg/day DCS with repetitive TMS, as proposed here, has been demonstrated to enhance remission and response rates in patients with depression in two weeks, with no serious adverse events reported in this trial of 50 patients. Importantly, previous studies examining DCS efficacy as an adjunct to antidepressant regimens also found no adverse events and a trend-level improvement of depression severity, and another evaluating safety for treatment of TB in patients with and without depression found an overall decrease in depression severity over treatment course. Combining DCS with LRD (NRX-101) should enhance these effects because it will modulate activity of both NMDA and 5-HT7 receptors in a manner that should reduce depressive symptoms. Indeed, Phase 2 clinical trial data showed clinical superiority of NRX-101 over LRD only for treating bipolar disorder, with no serious adverse events in 22 completers.

For transparency, investigators note here that while depression is listed as a contraindication when DCS is used to treat tuberculosis, the label reflects risks associated with DCS doses approximately 20 times higher than those used for modulation of neuroplasticity. Higher doses of DCS produce opposite (antagonistic) effects of the NMDA receptor relative to lower doses (agonistic), and dose-dependent side effects such as depression present at the highest doses (Lexicomp). investigators plan to use small doses of DCS that, when paired with TMS, have been shown to reduced depressive symptoms with minimal side effects.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • Fase temprana 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Prem Ganesh, MS
  • Número de teléfono: 617-855-2153
  • Correo electrónico: pganesh@mgb.org

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Massachusetts
      • Belmont, Massachusetts, Estados Unidos, 02478
        • Reclutamiento
        • McLean Hospital
        • Contacto:
          • Prem Ganesh, MS
          • Número de teléfono: 617-855-2153
          • Correo electrónico: pganesh@mgb.org
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or Female adults (+18 years old)
  • from any ethnic or racial background
  • with moderate to severe depression, as indicated by scores of: ≥ 20 on the MADRS; AND ≥ 10 on PHQ-9.

Exclusion Criteria:

  • History of manic or hypomanic symptoms;
  • lifetime DSM-5 psychotic spectrum disorder or current clinically significant psychotic symptoms;
  • active alcohol or substance use disorder that, in the opinion of a study physician/PI, is of sufficient severity to impede engagement in treatment or is associated with significant risk of medical withdrawal;
  • anorexia nervosa or eating disorder not otherwise specified that, in the opinion of a study physician/PI, is of sufficient severity to be associated with significant medical risks;
  • current suicide risk sufficient to require immediate hospitalization (C-SSRS 4 or above)
  • history of traumatic brain injury (TBI) that, in the opinion of a study physician/PI, would significantly increase risk of seizure;
  • any other significant neurological disorder likely to increase risk of seizure, in the opinion of a study physician/PI;
  • diagnosed neurodevelopmental disorder (e.g., autism, Down syndrome; Ehlers-Danlos Syndrome);
  • current diagnosis of delirium or greater than mild dementia;
  • cognitive disorder secondary to a general medical condition suggesting probable TBI or intellectual impairment;
  • Pregnant and breastfeeding women are not eligible to participate in this study excluded in line with prior work using DCS and TMS (Rossi et al., 2021). To confirm eligibility, all female participants of childbearing potential will be required to undergo a urine pregnancy test prior to enrollment. Additionally, if at any point during the study the participant or the researcher suspects that the participant may have become pregnant, a urine pregnancy test will be administered to ensure continued eligibility;
  • Participants with contraindications to TMS (e.g., metal in head or neck area), or at increased risk for adverse events (e.g., seizure history or markedly heightened risk factors for seizures, serious medical problems, implanted devices) will be excluded;
  • Participants with a known allergy to DCS or LRD will be excluded;
  • fMRI contraindications follow those of TMS and individuals unable to safely receive either will be excluded;
  • No healthy volunteers will be recruited;
  • No patients with involuntary hospitalization status will be recruited.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Open-label TMS + NRX-101

20 sessions of active iTBS combined with a single dose of NRX-101

Transcranial Magnetic Stimulation (TMS): TMS involves a procedure where a coil is placed on the scalp and magnetic energy enters the participant's brain in pulses. TMS does not alter consciousness or impose restrictions of any kind on a participant after a session. Single pulses of TMS are delivered to probe cortical excitability, as a surrogate of plasticity, before and after each treatment session. Excitability is measured with neurophysiology including electromyography (EMG). Repetitive TMS (rTMS) administered in the study is delivered in a pattern protocol called intermittent-theta burst stimulation (iTBS) which has been FDA-cleared for-and shown to be effective in-the treatment of depression. We aim to deliver up to 20 sessions per day but can adapt for patient or staff related scheduling challenges or tolerability

Otros nombres:
  • Estimulación Magnética Transcraneal
  • iTBS

NRX-101 is a combination capsule of fixed dose d-cycloserine (175 mg) and lurasidone (8.25 mg)

Otros nombres:
  • lurasidone and d-cycloserine

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
Periodo de tiempo: From day of treatment to six weeks after treatment

Clinician-rated measure of depressive symptom severity. Higher scores indicate worse symptoms. The minimum is 0, maximum is 60.

From day of treatment to six weeks after treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Hamilton Depression Rating Scale (HAM-D)
Periodo de tiempo: From day of treatment to six weeks after treatment

Clinician-rated measure of depressive symptom severity. Higher score indicate worse symptoms. The minimum is 0, the maximum is 52.

From day of treatment to six weeks after treatment
Patient Health Questionnaire 9-item (PHQ-9)
Periodo de tiempo: From day of treatment to six weeks after treatment

self-rated measure of depression symptom severity. Higher scores indicate worse symptoms. The minimum is 0, and the maximum is 27.

From day of treatment to six weeks after treatment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Kerry Ressler, MD, PhD, Mclean Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de octubre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2026

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

18 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

20 de agosto de 2026

Publicado por primera vez (Actual)

25 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data will be shared through the National Institute of Mental Health Data Archive (NDA) in accordance with NIMH data sharing expectations. Data to be shared will include demographic information and clinical scale scores. Data will be submitted to the NDA following standard de-identification procedures and will be made available to qualified researchers through the NDA data access request process.

Marco de tiempo para compartir IPD

Data will be submitted to the NDA within 1 year of primary study completion or upon publication of primary results, whichever comes first.

Criterios de acceso compartido de IPD

Data will be accessible to qualified researchers through the NIMH Data Archive data access request process.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir